| Richard Y Pak, MD | |
|
3939 Central Pike, Hermitage, TN 37076 | |
| (615) 883-2331 | |
| (615) 391-1785 |
| Full Name | Richard Y Pak |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 3939 Central Pike, Hermitage, Tennessee |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710968037 | NPI | - | NPPES |
| 3334384 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD 40197 (Tennessee) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Amedisys Home Health | Nashville, TN | Home health agency |
| Tristar Summit Medical Center | Hermitage, TN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advanced Diagnostic Imaging Pc | 7315848140 | 545 |
News Archive
Johns Hopkins undergraduates have invented a device to improve cell therapy for diabetes patients by anchoring transplanted insulin-producing cells inside a major blood vessel.
A large study confirms several factors that can distinguish patients with bipolar depression from those with unipolar depression, including higher trait impulsivity, aggression and hostility.
Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.
› Verified 7 days ago
| Entity Name | Advanced Diagnostic Imaging Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1093741464 PECOS PAC ID: 7315848140 Enrollment ID: O20040115000677 |
News Archive
Johns Hopkins undergraduates have invented a device to improve cell therapy for diabetes patients by anchoring transplanted insulin-producing cells inside a major blood vessel.
A large study confirms several factors that can distinguish patients with bipolar depression from those with unipolar depression, including higher trait impulsivity, aggression and hostility.
Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Richard Y Pak, MD 3939 Central Pike, Hermitage, TN 37076 Ph: (615) 883-2331 | Richard Y Pak, MD 3939 Central Pike, Hermitage, TN 37076 Ph: (615) 883-2331 |
News Archive
Johns Hopkins undergraduates have invented a device to improve cell therapy for diabetes patients by anchoring transplanted insulin-producing cells inside a major blood vessel.
A large study confirms several factors that can distinguish patients with bipolar depression from those with unipolar depression, including higher trait impulsivity, aggression and hostility.
Exelixis, Inc. today announced preliminary results from BRIM7, an ongoing Phase Ib trial conducted by Roche and Genentech, Exelixis' collaborator and a member of the Roche Group, of the BRAF inhibitor (BRAFi) vemurafenib in combination with the MEK inhibitor GDC-0973 in patients with locally advanced/unresectable or metastatic melanoma carrying a BRAFV600 mutation.
Xenon Pharmaceuticals Inc. announced today that it has initiated a phase 2 clinical trial evaluating its novel topical XEN402 therapy for the treatment of PHN.
› Verified 7 days ago
Robert Bernard Gaston Jr., MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3939 Central Pike, Hermitage, TN 37076 Phone: 615-883-2331 Fax: 615-391-1785 | |
John M Pope, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5225 Old Hickory Boulevard, Suite 205, Hermitage, TN 37076 Phone: 615-938-7190 Fax: 615-938-7191 | |
Angela Lee Willis, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 5651 Frist Blvd, Suite 713, Hermitage, TN 37076 Phone: 615-316-5662 Fax: 615-316-5666 | |
Dr. Steven Ross Kinney, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 244 Jackson Meadows Dr, Hermitage, TN 37076 Phone: 615-874-9888 Fax: 615-883-6899 | |
Dr. Robert William Guth, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 4777 Andrew Jackson Pkwy, Suite 101, Hermitage, TN 37076 Phone: 615-889-0134 Fax: 615-889-0135 | |
Mindi Hamby, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3939 Central Pike, Hermitage, TN 37076 Phone: 615-883-2331 Fax: 615-391-1785 | |
Kathy Grove, NP Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 5651 Frist Blvd Ste 200, Hermitage, TN 37076 Phone: 615-885-0200 |